Accueil / Formation Recherche / Publications / Publications Cytopénies auto-immunes (PTI/AHAI/Evans)

Publications Cytopénies auto-immunes (PTI/AHAI/Evans)

Systematic Detection of Portal or Splenic Vein Thrombosis after Splenectomy for Immune Cytopenia.

Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults.

Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. 


Treatment with cyclosporin in auto-immune cytopenias in children: The experience from the French cohort OBS’CEREVANCE.

Pathogenesis of immune thrombocytopenia. Audia S et al. Autoimmun Rev. 2017 Jun;16(6):620-632.

Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. Ducassou S et al. Br J Haematol. 2017 Jun;177(5):751-758.

Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Aladjidi N et al. Pediatr Blood Cancer. 2017 Jul 27.

Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP). Roche O et al. Am J Hematol. 2017 May;92(5):E79-E81.

A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Michel M et al. Am J Hematol. 2017 Jan;92(1):23-27.

Long-term complications of splenectomy in adult immune thrombocytopenia. Thai LH et al. Medicine (Baltimore). 2016 Nov;95(48):e5098

La plus grande série au monde de syndromes d' Evans chez l'enfant, publiée par le groupe CEREVANCE: Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort. Front Pediatr. 2015 Sep 29;3:79.

Stabilité du nombre de patients adultes hospitalisés pour un PTI chaque année en France : le recours aux IgIV concernent la moitié d’entre eux, le recours au rituximab est stable et le recours à la splénectomie tend à décroître: Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012. Br J Haematol. 2015 Mar 31.

Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2015 May 15.

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
 
Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
 
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.

Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
 
Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases.
 
Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab.


 

ACTUALITÉS

Le Pr Eric Oksenhendler récompensé "Médecin de l'année 2018" pour son travail sur la maladie de Castleman

Le congrès des Rencontres RARE revient pour sa 6ème édition, les 5 & 6 novembre 2019
Cité des Sciences et de l'Industrie, Paris
Ouverture des candidatures pour l'ASH 2019 à Orlando
La filière MaRIH recherche deux internes "reporters" pour participer à l'ASH !
Voir toutes les actualités

AGENDA

Du 27-09-2019 au 29-09-2019 : 16èmes Journées de l’Association des Internes en Hématologie, Lyon


04-10-2019 : 7ème Journée régionale interactive maladies rares immuno-hématologiques MaRIH "Océan Indien", Saint-Denis (La Réunion)


04-10-2019 : Journée annuelle du centre de référence des aplasies médullaires acquises et constitutionnelles, Paris
Voir tout l'agenda